Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 17/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6189735 | 0.74 | PTGER4 (0.52) | PTGER4ALDH1A1HPGD | |
| SCHEMBL1756460 | 0.70 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL3537543 | 0.68 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL3535869 | 0.68 | PTGER4 (0.42) | PTGER4ALDH1A1HPGDCYP1A2GAA | |
| SCHEMBL14072914 | 0.66 | APEX1 (0.49) | PTGER4ALDH1A1HPGD | |
| SCHEMBL5712864 | 0.66 | KMT2A (0.44) | ALDH1A1HPGDGAAPKM | |
| SCHEMBL2036102 | 0.66 | LMNA (0.42) | ALDH1A1CYP1A2GAACYP2C9PKM | |
| SCHEMBL3533268 | 0.66 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL27519880 | 0.65 | ACMSD (0.53) | — | |
| SCHEMBL29742912 | 0.64 | PTGER4 (0.61) | PTGER4ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, NR4A1, NR4A2 | PTGER4 1/4885ALDH1A1 1522/4885HPGD 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.